Small Molecules and / or Biologics Medical Writing Subject Matter Expert Support Services
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $250,000 to $700,000
- Set-aside
- Total Small Business
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
-
- Nagarajan Rangarajan nagarajan.rangarajan@nih.gov
- Daniel Federline daniel.federline@nih.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health forecasts a new requirement for Small Molecules and/or Biologics Medical Writing Subject Matter Expert Support Services under NAICS 541715, with a total small business set-aside, an estimated solicitation release on March 1, 2026, and an estimated award on September 1, 2026. The services support the BPN small molecule and HEAL programmes, which have operated for more than 13 years to accelerate drug development for neurological diseases and non-opioid pain medications. Subject matter experts, including those in Regulatory Affairs, guide principal investigators through drug development alongside retired executive-level scientific managers from pharma, and the source describes these contracts as essential to current and future drug development projects.
The estimated award value range is $250,000 to $700,000. The source describes the contracts as 1-year labor contracts with 2 option years, and as small business contracts under the Simplified Acquisition Threshold. Points of contact are Nagarajan Rangarajan (nagarajan.rangarajan@nih.gov) and Daniel Federline, Contracting Officer (daniel.federline@nih.gov), both at the National Institutes of Health.
Forecast text
BPN small molecule and HEAL programmes have been in operation for more than 13 years. The aim of these programmes is to accelerate the development of drugs for neurological diseases and non-opioid pain medications. The programmes guide PIs through the drug development process using a number of retired executive level, scientic managers from Pharma. A number of BPN and HEAL projects have successfully completed FDA IND applications and progressed to Phase 1 trials. A number of projects have been purchased by venture capital and pharma companies. SMEs in various disciplines such as Regulatory Affairs are engaged on 1-year labor contracts with 2 option years. These are small business contracts under Simplied Acquisition Threshold . These are essential contracts without which current and future drug development projects will not be able to progress
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast